Sohouli Mohammad Hassan, Eslamian Ghazaleh, Rohani Pejman, Zand Hamid, Guimarães Nathalia Sernizon
Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Cellular and Molecular Nutrition, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC Nutr. 2024 Aug 13;10(1):111. doi: 10.1186/s40795-024-00921-2.
Recent evidence shows the role of sirtuin 1(SIRT1), a family of evolutionarily conserved proteins, as a potential therapeutic target in the prevention and treatment of obesity and metabolic diseases. Some evidence shows the moderating effects of weight loss interventions on this factor. However, the findings are contradictory. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of weight loss interventions on SIRT 1 modulation.
For this study, we searched four electronic databases using predefined keywords from inception until March 2024. We includedrandomized controlled trials that evaluated the effect of weight reduction strategies on SIRT1 levels. The random-effects model analysis was used to obtain the pooled weighted mean difference (WMD) and 95% confidence intervals (95% CI). The meta-analysis was conducted using RevMan version 5.3 software and Stata version 12.0.
Twelve studies with 627 volunteers were included. The pooled findings showed that weight loss interventions have no significant effect on the modulation of SIRT1 compared to the control group (pooled WMD of 0.58 ng/mL; 95% confidence interval [CI] -0.17 to 1.33; p = 0.130). However, subgroup analysis showed that weight loss interventions significantly modulate SIRT1 at metabolic disease (WMD: 1.2 ng/mL, 95% CI: 0.11 to 2.62, I = 82.9%). In addition, subgroup findings indicated health status and body mass index (BMI) as sources of high and potential heterogeneity.
Based on the findings, weight loss therapies in individuals having a metabolic disorder appear to generate a considerable increase in SIRT1 levels.
最近的证据表明，沉默调节蛋白1（SIRT1）作为进化上保守的蛋白质家族，在肥胖和代谢性疾病的预防和治疗中具有潜在的治疗靶点作用。一些证据显示了体重减轻干预措施对该因子的调节作用。然而，研究结果相互矛盾。为了从这些研究中获得更好的观点，本研究旨在全面调查体重减轻干预措施对SIRT1调节的影响。
在本研究中，我们使用预定义的关键词，从数据库建立之初到2024年3月，检索了四个电子数据库。我们纳入了评估体重减轻策略对SIRT1水平影响的随机对照试验。采用随机效应模型分析来获得合并加权平均差（WMD）和95%置信区间（95%CI）。使用RevMan 5.3软件和Stata 12.0软件进行荟萃分析。
纳入了12项研究，共627名志愿者。汇总结果显示，与对照组相比，体重减轻干预措施对SIRT1的调节没有显著影响（合并WMD为0.58 ng/mL；95%置信区间[CI]为-0.17至1.33；p = 0.130）。然而，亚组分析表明，体重减轻干预措施在代谢性疾病中对SIRT1有显著调节作用（WMD：1.2 ng/mL，95%CI：0.11至2.62，I² = 82.9%）。此外，亚组研究结果表明健康状况和体重指数（BMI）是高异质性和潜在异质性的来源。
基于这些发现，患有代谢紊乱的个体进行体重减轻治疗似乎会使SIRT1水平显著升高。
